StockData

Atara Biotherapeutics vs Innate Pharma

ATRA and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

atraAtara Biotherapeutics$8.23−33.1% in 1 yeariphaInnate Pharma$1.59−30.9% in 1 year

How ATRA and IPHA compare

Innate Pharma grew revenue faster over the last twelve months (−55.2% versus −97.4% for Atara Biotherapeutics).

Atara Biotherapeutics scores higher on the StockData Score (7 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATRAIPHA
Size and price
Market cap$82.6M–
Share price$8.23$1.59
Change, 1 year−33.1%−30.9%
Change, 5 years−98.2%−68.3%
Beta (5Y)1.650.95
Employees14181
StockData Score
Total score7 (better)0
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S20.8×–
Growth
Revenue growth (TTM)−97.4%−55.2% (better)
Revenue growth, 5Y average–−33.6%
Net income growth (TTM)−162%–
Profitability
Operating margin−344% (better)−600%
Net margin−369%–
FCF margin–−587%
Financial health
Interest coverage–−17.3×
Current ratio1.72 (better)0.60
Altman Z-score−153.99–
Piotroski F-score5–
Dividends and buybacks
Buyback yield−10.4%–
Shareholder yield−10.4%–
Ownership
Held by institutions44.5%0.21%
Held by insiders55.5%16.2%
Insider net buying, 12 months$2.0M–
Short interest, % of float6.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.